Information regarding trading suspension

STOCKHOLM, 13 February 2012 - Karo Bio AB (publ) estimates to provide information on Tuesday morning related to the Stockholm Stock Exchange's decision to suspend trading in its shares.

About Karo Bio
Karo Bio is a pharmaceutical company focused on the research and development of innovative drugs for large medical needs. The company runs a number of drug development projects within the indication areas cardiovascular and metabolic diseases, neuropsychiatry, inflammation, autoimmune diseases, cancer and women’s health. An important foundation for the company’s activities is its unique knowledge of nuclear receptors as target proteins for the development of novel pharmaceuticals, as well as related mechanisms of action. Karo Bio is based in Huddinge, Sweden, has around 70 employees and is listed on NASDAQ OMX Stockholm.

Karo Bio publishes this information in accordance with the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was published on February 13, 2012, at 08:30 am CET.

This press release is also available online at www.karobio.com and www.newsroom.cision.com

Tags: